Saeed Shoja Shafti1, Abbas Azizi Khoei2. 1. University of Social Welfare and Rehabilitation Sciences (USWR), Razi Psychiatric Hospital, Tehran, Iran. 2. Razi Psychiatric Hospital, Tehran, Iran.
Abstract
BACKGROUND: Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia and so this may contribute to the cognitive impairments of schizophrenic patients. Because such deficits do not respond to neuroleptic treatment, different approaches have been done by acetylcholinesterase inhibitors (AChEIs). The objective of the present assessment was to evaluate the safety and clinical effects of rivastigmine, as an adjunctive drug, on the clinical symptoms of schizophrenia. METHODS: A total of 46 patients with a diagnosis of schizophrenia entered into a 12-week, double-blind, clinical trial for random assignment to rivastigmine or placebo, as adjuvant to their current antipsychotic medication. Positive and Negative Symptom Scale (PANSS) and Mini Mental State Examination (MMSE) had been used as the primary outcome measures. Clinical Global Impressions- Improvement (CGI-I) Scale and Extrapyramidal Symptom Rating Scale (ESRS) had been used as the secondary measures. Treatment efficacy was evaluated by a Student's t test and repeated-measures analysis of variance (ANOVA). Statistical significance was defined as a two-sided p value ⩽ 0.05. Cohen's standard (d) and correlation measures of effect size (r) had been calculated for comparing baseline to endpoint changes. RESULTS: According to the findings, except for significant enhancement of MMSE by rivastigmine (p < 0.001), no significant improvement in PANSS (negative symptoms), PANSS (positive symptoms), and PANSS (general psychopathology) was evident in the target group. Also, except for significant improvement of CGI-I by rivastigmine in intragroup analysis, no significant effectiveness was evident in between-group analysis or repeated-measures ANOVA. ESRS, also, did not show any significant alteration in either group. Effect size (ES) analysis showed a large improvement in MMSE by rivastigmine. CONCLUSIONS: According to the findings, while rivastigmine could not induce significant improvement of positive and negative symptoms of schizophrenia, it caused significant enhancement of cognitive function in this group of patients.
RCT Entities:
BACKGROUND: Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia and so this may contribute to the cognitive impairments of schizophrenicpatients. Because such deficits do not respond to neuroleptic treatment, different approaches have been done by acetylcholinesterase inhibitors (AChEIs). The objective of the present assessment was to evaluate the safety and clinical effects of rivastigmine, as an adjunctive drug, on the clinical symptoms of schizophrenia. METHODS: A total of 46 patients with a diagnosis of schizophrenia entered into a 12-week, double-blind, clinical trial for random assignment to rivastigmine or placebo, as adjuvant to their current antipsychotic medication. Positive and Negative Symptom Scale (PANSS) and Mini Mental State Examination (MMSE) had been used as the primary outcome measures. Clinical Global Impressions- Improvement (CGI-I) Scale and Extrapyramidal Symptom Rating Scale (ESRS) had been used as the secondary measures. Treatment efficacy was evaluated by a Student's t test and repeated-measures analysis of variance (ANOVA). Statistical significance was defined as a two-sided p value ⩽ 0.05. Cohen's standard (d) and correlation measures of effect size (r) had been calculated for comparing baseline to endpoint changes. RESULTS: According to the findings, except for significant enhancement of MMSE by rivastigmine (p < 0.001), no significant improvement in PANSS (negative symptoms), PANSS (positive symptoms), and PANSS (general psychopathology) was evident in the target group. Also, except for significant improvement of CGI-I by rivastigmine in intragroup analysis, no significant effectiveness was evident in between-group analysis or repeated-measures ANOVA. ESRS, also, did not show any significant alteration in either group. Effect size (ES) analysis showed a large improvement in MMSE by rivastigmine. CONCLUSIONS: According to the findings, while rivastigmine could not induce significant improvement of positive and negative symptoms of schizophrenia, it caused significant enhancement of cognitive function in this group of patients.
Authors: Salma R I Ribeiz; Débora P Bassitt; Jony A Arrais; Renata Avila; David C Steffens; Cássio M C Bottino Journal: CNS Drugs Date: 2010-04 Impact factor: 5.749
Authors: Michael H Rosenbloom; Richard Finley; Melvin M Scheinman; Mitchell D Feldman; Bruce L Miller; Gil D Rabinovici Journal: Alzheimer Dis Assoc Disord Date: 2010 Apr-Jun Impact factor: 2.703
Authors: Rajiv Tandon; R H Belmaker; Wagner F Gattaz; Juan J Lopez-Ibor; Ahmed Okasha; Bruce Singh; Dan J Stein; Jean-Pierre Olie; W Wolfang Fleischhacker; Hans-Juergen Moeller Journal: Schizophr Res Date: 2008-02-19 Impact factor: 4.939
Authors: Sylvie Chouinard; Emmanuel Stip; Julie Poulin; Jean-Pierre Melun; Roger Godbout; François Guillem; Henri Cohen Journal: Curr Med Res Opin Date: 2007-03 Impact factor: 2.580
Authors: Richard S E Keefe; Terry E Goldberg; Philip D Harvey; James M Gold; Margaret P Poe; Leigh Coughenour Journal: Schizophr Res Date: 2004-06-01 Impact factor: 4.939
Authors: Igne Sinkeviciute; Marieke Begemann; Merel Prikken; Bob Oranje; Erik Johnsen; Wan U Lei; Kenneth Hugdahl; Rune A Kroken; Carina Rau; Jolien D Jacobs; Silvia Mattaroccia; Iris E Sommer Journal: NPJ Schizophr Date: 2018-10-25